This blood spot is more effective than aspirin in preventing heart attacks

Aspirin is one The most desirable drugs in the world, which have been recommended for decades as a way of protecting heart attacks and shocks in patients with risk. However, the new study found that Clopidogrel, another common blood, or anticoagulant, is more effective in preventing serious heart attacks and strikes and does not carry additional risk.

The finding is the result of the research conducted by the International Team of Scientists from the United States, Great Britain, Switzerland, Australia and Japan. Their work is meta-analysis – a study that collects and analyzes the results of several smaller studies, with the aim of achieving a more reliable conclusion by looking at a larger amount of data. A total of this meta-analysis looked at clinical data from almost 29,000 arterial coronary disease (CAD), a condition in which fats in arteries, which can lead to secondary effects such as heart attacks and heart attacks.

Experts conducted a systematic search of medical databases such as pubmed, scopus, web science and embe in order to find randomized treatment tests for CAD published until 12. April 2025. years. The goal was to identify the paperwork in relation to the efficiency of aspirin versus clopidogreli, heart attacks and strikes and strikes and strikes and hits and strikes and strikes and strikes and strikes and strikes and strikes and strikes.

The analysis focused on seven investigations involved in clinical information of people with certified cases of CAD treated aspirin or clopidogrel on average 2.3 years. After monitoring of 5.5 years, researchers noted that those who received Clopidogrel had a 14 percent lower risk of a great cardiovascular event compared to those treated aspirin.

Finally, the team concluded that these finds “add evidence” that Clopidogrel is a superior aspirin to prevent major harmful heart and cerebrovascular events. In the researcher’s view, these findings support Clopidogrel over aspirin in patients with the established CAD to try to prevent great complications as a result of their condition, such as a heart attack. The findings were published in the magazine Lancet.

In terms of mortality and bleeding, meta-analysis concluded that the rates were similar in both groups, which confirmed that Clopidogrel was as safe as aspirin.

“How much in our knowledge, clopidogrel monotherapy is the only treatment of antiplatelic who consistently demonstrated more efficiency than aspirin without compromising security,” said researchers in the newspapers.

The discovery could be internationally to transform medical guidelines. Clopidogrel is widely available, affordable drug with reliable generic versions, characteristics that would facilitate involvement in routine clinical practices. However, experts emphasize that it is necessary to assess the economy of clopidogrel and its performance in a varied population to support its involvement in treatment standards.

Cardiovascular diseases are the leading cause of death in the world. According to the World Health Organization, it was estimated 17.9 million people died every year from these conditions. More than four of each five of these deaths are due to coronary disease or stroke. The new research suggests that Clopidogrel could become a key alternative to combat this problem of public health, whose frequency continues to rise around the world.

This story originally appeared Wired Spanish and has been translated from Spanish.